BiotechTube

Dasatinib + Osimertinib

Phase 1/2Terminated
0 watching 0 views this week⚡ Active
41
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

EGFR Gene Mutation

Conditions

EGFR Gene Mutation, Nonsmall Cell Lung Cancer

Trial Timeline

Oct 1, 2016 → Mar 3, 2023

NCT ID
NCT02954523

About Dasatinib + Osimertinib

Dasatinib + Osimertinib is a phase 1/2 stage product being developed by AstraZeneca for EGFR Gene Mutation. The current trial status is terminated. This product is registered under clinical trial identifier NCT02954523. Target conditions include EGFR Gene Mutation, Nonsmall Cell Lung Cancer.

Hype Score Breakdown

Clinical
13
Activity
8
Company
10
Novelty
4
Community
3

Clinical Trials (1)

NCT IDPhaseStatus
NCT02954523Phase 1/2Terminated

Competing Products

20 competing products in EGFR Gene Mutation

See all competitors
ProductCompanyStageHype Score
YH25448YuhanPhase 1/2
41
YH32364YuhanPhase 1/2
41
Datopotamab deruxtecanDaiichi SankyoPre-clinical
23
HER3-DXdDaiichi SankyoPre-clinical
23
ASP8273Astellas PharmaPhase 2
52
radio-labeled naquotinib + naquotinibAstellas PharmaPhase 1
33
erlotinibAstellas PharmaPhase 1
33
ASP8273 Capsules + ASP8273 Capsules AAstellas PharmaPhase 2
52
famitinib po + HS-10296 poJiangsu Hengrui MedicinePhase 2
52
ABT-414AbbViePre-clinical
23
AZD9291 40 mg + AZD9291 80 mgAstraZenecaPhase 1
33
Osimertinib-based adaptive treatment + Osimertinib 80 MGAstraZenecaPhase 2
52
AZD9291 + MEDI4736AstraZenecaPhase 3
77
EGFR TKIs (gefitinib, erlotinib, afatinib, et al)AstraZenecaPre-clinical
23
AZD9291AstraZenecaPre-clinical
23
OsimertinibAstraZenecaPhase 2
52
AZD9291 80mg oral each dayAstraZenecaPhase 3
77
Tremelimumab + DurvalumabAstraZenecaPhase 2
52
OsimertinibAstraZenecaPhase 2
52
AZD3759 + AZD9291AstraZenecaPhase 1
33

Other Products from AstraZeneca

QuetiapineApproved
85
Dapagliflozin 5 mg + Placebo tabletApproved
85
QuetiapineApproved
85
Ticagrelor + ClopidogrelApproved
85
DurvalumabApproved
85